12,372 trials
Iron Deficiency Anaemia · Iron Deficiency Anemia
Primary: Change in Hemoglobin (Hb) From Baseline to Week 8 — 2.49; 2.49 g/dL
Poliomyelitis
Primary: Number of Participants Experiencing Any Systemic Reactogenicity, by Maximum Severity — 187; 179; 175; 149 Participants
Encephalitis, Japanese B
Primary: Percentage of Participants With Seroprotection for Measles 4 Weeks After Vaccination — 1.1; 0.0; 0.0; 88.6 percentage of participants
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Geometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, And W Antibodies Following Vaccination With 3 Lots of MenACYW Conjugate Vaccine — 84.9; 96.5; 97.9; 326…
Depressive Disorder, Major
Primary: Time to First Relapse During the First 52 Weeks of the Double-Blind Treatment Period — 232; 225; 336 Days — p=0.5305
Healthy Volunteers
Primary: Cohort 1: Area Under the Concentration-time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t) of M3 Metabolite — 117.518; 163.615 h*pg/mL
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Efficacy Endpoint: Responder Rate at End of Study — 32 Participants — p=<0.0001
Type 1 Diabetes
Primary: Change in HbA1c From Baseline to 24 Weeks — 0.14; 0.11 percent
Dengue Fever · Dengue Hemorrhagic Fever · Human Papillomavirus Disease
Primary: Geometric Mean Titers (GMTs) Against Each Cervarix Human Papillomavirus (HPV) Antigen (HPV-16 and HPV-18) 28 Days After Last Cervarix Vaccination in the Previously…
Cognitive Impairment · Metastatic Malignant Neoplasm in the Brain · Solid Neoplasm
Primary: Time to Neurocognitive Failure — 68.2; 59.3 percentage of participants — p=0.029
Iron Deficiency Anaemia · Iron Deficiency Anemia · Chronic Kidney Disease
Primary: Change in Hemoglobin (Hb) From Baseline to Week 8 — 1.22; 1.14 g/dL
Ovarian Cancer
Primary: Progression-free Survival by Independent Review Committee — 3.5; 3.6 months — p=0.6294
Asthma
Primary: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 — 2.383; 2.387; 2.250; 2.176 litre (L) — p=<0.001
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Progression-free Survival (PFS) — 65.12; 14.32 Months — p=< 0.0001
Chronic Iron Overload
Primary: Overview of Number of Participants With Adverse Events — 52; 20; 14; 2 number of participants